Sartorius Unveils Octet R8e System for Advanced Biomolecular Interaction Analysis
ByAinvest
Sunday, May 25, 2025 10:38 pm ET1min read
AG--
The Octet R8e system leverages Sartorius' proprietary BLI technology, providing next-level sensitivity for accurate data generation at the lowest detection limits. This allows for the analysis of low-molecular weight ( 100 Da) and low-abundance (10 pM) analytes, broadening the dynamic range and improving detection limits [1]. Compatibility with 96- and 384-well plate formats offers additional flexibility in assay design, enabling customization to each study's unique scale, complexity, and cost requirements [1].
A notable feature of the Octet R8e is its advanced evaporation control in the 96-well plate format. This innovation preserves sample integrity, allowing for extended runtimes of up to 16 hours. The new evaporation cover minimizes sample evaporation, ensuring accurate measurements over extended assay durations without manual intervention [1].
Nilshad Salim, Product Manager of Octet® Systems at Sartorius, highlighted the system's capabilities: "The combination of high sensitivity and the ability to reduce sample size to 40 μL with our custom 384-well microplates gives researchers maximum freedom and significant cost efficiencies, without sacrificing data quality" [1]. The advanced evaporation protection is a game changer, supported by data showing excellent reproducibility between replicates over 16-hour experiments [1].
The Octet R8e system is designed to accelerate biopharmaceutical research across various stages, from drug discovery to development, bioprocessing, and quality control. With a large global install-base in regulated environments across pharma, biotech, and CRO organizations, the Octet R8e offers a powerful and streamlined alternative to SPR-based platforms [1].
References:
[1] https://www.sartorius.com/en/company/newsroom/product-news/sartorius-launches-the-octet-r8e-system-real-time-label-free-biomolecular-interaction-analysis-with-unprecedented-sensitivity-and-efficiency-1690702
[2] https://www.news-medical.net/news/20250524/Sartorius-launches-the-Octetc2ae-R8e-System-Real-time-label-free-biomolecular-interaction-analysis-with-unprecedented-sensitivity-and-efficiency.aspx
DAO--
Sartorius launches the Octet R8e biolayer interferometry (BLI) system, providing researchers with advanced detection capabilities for real-time, high-throughput analysis of protein-protein and biomolecular interactions. The system offers higher sensitivity, flexible assay design, and longer run times, expanding the industry-leading fluidic-free Octet BLI portfolio. It is designed for applications requiring higher sensitivity, flexible assay design, and longer run times.
Sartorius AG, a leading life science company, has launched the Octet R8e biolayer interferometry (BLI) system, marking a significant advancement in real-time, high-throughput analysis of protein-protein and biomolecular interactions. The new system expands Sartorius' industry-leading fluidic-free Octet BLI portfolio, offering enhanced sensitivity, flexible assay design, and extended run times [1].The Octet R8e system leverages Sartorius' proprietary BLI technology, providing next-level sensitivity for accurate data generation at the lowest detection limits. This allows for the analysis of low-molecular weight ( 100 Da) and low-abundance (10 pM) analytes, broadening the dynamic range and improving detection limits [1]. Compatibility with 96- and 384-well plate formats offers additional flexibility in assay design, enabling customization to each study's unique scale, complexity, and cost requirements [1].
A notable feature of the Octet R8e is its advanced evaporation control in the 96-well plate format. This innovation preserves sample integrity, allowing for extended runtimes of up to 16 hours. The new evaporation cover minimizes sample evaporation, ensuring accurate measurements over extended assay durations without manual intervention [1].
Nilshad Salim, Product Manager of Octet® Systems at Sartorius, highlighted the system's capabilities: "The combination of high sensitivity and the ability to reduce sample size to 40 μL with our custom 384-well microplates gives researchers maximum freedom and significant cost efficiencies, without sacrificing data quality" [1]. The advanced evaporation protection is a game changer, supported by data showing excellent reproducibility between replicates over 16-hour experiments [1].
The Octet R8e system is designed to accelerate biopharmaceutical research across various stages, from drug discovery to development, bioprocessing, and quality control. With a large global install-base in regulated environments across pharma, biotech, and CRO organizations, the Octet R8e offers a powerful and streamlined alternative to SPR-based platforms [1].
References:
[1] https://www.sartorius.com/en/company/newsroom/product-news/sartorius-launches-the-octet-r8e-system-real-time-label-free-biomolecular-interaction-analysis-with-unprecedented-sensitivity-and-efficiency-1690702
[2] https://www.news-medical.net/news/20250524/Sartorius-launches-the-Octetc2ae-R8e-System-Real-time-label-free-biomolecular-interaction-analysis-with-unprecedented-sensitivity-and-efficiency.aspx

Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue

Comments
No comments yet